Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Candel (CADL) stock fell 20% Tuesday after the company reported final overall survival data from a Phase 2 study of its drug ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

Candel Therapeutics (CADL) announced final overall survival data from the completed randomized controlled phase 2 clinical trial of CAN-2409 ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop ...

Shares of Candel Therapeutics , Inc. (NASDAQ: CADL) climbed 8% following the announcement of favorable final survival data from their phase 2 trial of CAN-2409, a treatment for pancreatic cancer. The ...

The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.